Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus X TROZINE L A.
HISTAFED vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine